Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Description

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Conditions

Advanced Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Condition
Advanced Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

New Haven

Yale Cancer Center, New Haven, Connecticut, United States, 06511

Chicago

University of Illinois, Chicago, Illinois, United States, 60612

Cincinnati

The Christ Hospital Cancer Center, Cincinnati, Ohio, United States, 45219

Cleveland

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
  • * Age ≥ 18 years
  • * Adequate renal function
  • * Adequate liver function
  • * Adequate hematological function
  • * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • * Patients must not have clinically significant cardiac disease.
  • * Patients must not have known non-controlled CNS metastasis.
  • * Patients must not have active autoimmune disease or a documented history of autoimmune disease.
  • * Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
  • * Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
  • * Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • * Patients must not be women who are pregnant or breast feeding.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

BioAtla, Inc.,

Study Record Dates

2025-12-31